Download Unicorn Signals App

By EquityPandit

EquityPandit

EquityPandit
MARKETS

S&P BSE IPO Index Plunges 6%

Picture Source: Internet

Recently, shares of listed companies continued to be under pressure, with the S&P BSE IPO index falling 6 per cent on the BSE in Thursday’s intra-day trade. The sharp downfall happened after market sentiment turned sour after the Russian military launched an attack on Ukraine with reports of blasts in several major cities.

The S&P BSE IPO index, the top loser among all significant indices, was down 6 per cent at 9,293.40 on the BSE in intra-day trade. In comparison, the S&P BSE Sensex was down 3 per cent at 55,448 points. In the past three months, the IPO index has tanked 31 per cent against a 5 per cent decline in the benchmark index.

Latent View Analytics, Krsnaa Diagnostics, Nuvoco Vistas Corporation, CarTrade Tech, Windlas Biotech, RateGain Travel Technologies and PB Fintech were down 7 per cent to 11 per cent on the BSE.

Besides these, a total of 31 stocks, including Barbeque-Nation Hospitality, Macrotech Developers (Lodha), Nazara Technologies, and Go Fashion (India), hit their respective lows since their listing on the BSE.

Get Daily Prediction & Stocks Tips On Your Mobile


I would like to receive communication from EquityPandit via sms, email, whatsapp, Google RCS for offers, updates etc.
MARKETS

IRB Infra Shares Trade 2% Higher as Toll Collection Gains in March

Dhruva Kulkarni

Shares of IRB Infrastructure Developers Ltd gained 2% on Wednesday, 9 April 2025, after the company reported strong growth in toll revenue collection in March 2025 compared to March 2024. 

IRB Infrastructure said that toll income in March 2025 was Rs 557 crore, up from Rs 481 crore in March 2024. 

In FY2024-25 (FY25), IRB Infrastructure Developers Limited and its Private InvIT Associate IRB Infrastructure Trust increased toll revenue by over 23% over FY2023-24 (FY24). 

“This is much over and above the National Y-o-Y Toll Revenue growth of 12.5% for FY2024-25,” IRB Infrastructure highlighted. 

Notably, IRB Infrastructure also disclosed that the Company and the Trust generated Rs 6,360 crore in toll revenue for FY25, which was more than the Rs 5,169 crore recorded for FY24 as a whole.

You May Find This Interesting

Amitabh Murarka, deputy chief executive officer of IRB Infrastructure Developers Limited, said, “We take immense pride in the impressive 23 per cent growth in Toll Revenue for FY25, which significantly outpaces the national average of 12.5%. We are also pleased to report a strong finish to FY25, with approximately 16% year-on-year increase in our monthly Toll Revenue for March 2025.”

Murarka anticipates this growth trend to continue in FY26, driven by the Union Budget’s focus on important sectors such as tourism, transportation, and consumption-based industries, as well as the implementation of Toll Tariff adjustments. 

With an emphasis on roads and highways, IRB Infrastructure Developers Ltd (IRB) is a well-known integrated multi-national transport infrastructure developer.  IRB is the largest private toll road and highway developer in India, with over Rs 80,000 crore in assets distributed across 12 states, including the core business and two Infrastructure Investment Trusts (InvITs).

With more than 25 years of experience, IRB Infrastructure has built, tolled, maintained, and operated about 18,500 lane kilometres across the country, of which 15,500 are presently in use. The business has a significant market share of over 38% in the Toll-Operate-Transfer (TOT) sector and 12% in India’s North-South highway connection.

IRB Infrastructure has effectively finished thirteen concessions and transferred them to the relevant nodal organizations.  Eighteen Build-Operate-Transfer (BOT) projects, four TOT projects, and four HAM projects make up the IRB Group’s current portfolio of 26 road projects.

However, at 3:30 pm, the shares of IRB Infra closed 0.50% lower at Rs 45.49 on NSE.

Curious About IRB Infra? Ask the Analyst.

Ready to invest like a pro? Unicorn Signals app equips you with 100+ Free tools and knowledge you need to succeed. Download the Unicorn Signals app and gain access to daily stock lists and insightful market analysis and much more!

MARKETS

ITI Shares Rally 5% on Commencing Work for S-NOC

Ali Waghbakriwala

Shares of ITI Ltd rallied 5%, hitting an intraday high of Rs 254.40 on 9 April after the company announced that it had begun work on the State Network Operations Center (S-NOC) of the massive BharatNet Phase-III Project in Solan, Himachal Pradesh, in collaboration with BSNL.

In its regulatory filing, the company said, “S-NOC is a centralised location where ITI Limited will monitor and manage the performance, security, and availability of the project’s network infrastructure, ensuring efficient delivery of services.”

Moreover, the company was awarded lowest bidder (L1) status for the BharatNet Phase-III Project in the Andaman & Nicobar Islands, West Bengal, and Himachal Pradesh, with a total order value of Rs 5,050 crore.

ITI is a significant source of electronic manufacturing, specifically defence electronics goods and systems. The company provides a comprehensive variety of telecom products and solutions, including Switching, Transmission, Access, and Subscriber Premises equipment.  

You Might Be Interested In

The company operates cutting-edge manufacturing facilities in six locations: Bangalore (Karnataka), Mankapur (UP), Naini (UP), Rae Bareli (UP), Palakkad (Kerala), and Srinagar (J&K). 

Revenue for the company increased 1.08% to Rs 1,034.54 crore in Q3FY25 from Rs 1,016.20 crore in Q2FY25. The company’s net loss decreased from Rs 70.33 crore in Q2FY25 to Rs 48.88 crore during the quarter.

At 1:33 pm, the shares of ITI were trading 4.82% higher at Rs 254 on NSE.

Ask the analyst & get instant answer about ITI Ltd.

Tired of guessing stocks to trade in daily?
Unicorn Signals empowers you with powerful tools like daily stock scans for Intraday, Swing & Investing, Market Predictions and much more. Download the Unicorn Signals app today and take control of your investments!

MARKETS

FMCG Shares Gain as RBI Cuts Inflation Forecast 

Ali Waghbakriwala

Shares of fast-moving consumer goods (FMCG) were trading in the green despite weak market conditions on 9 April after the Reserve Bank of India’s (RBI) Monetary Policy Committee (MPC) slashed the inflation estimate for fiscal year 2026 from 4.2% to 4.0%. 

Reserve Bank of India, in its statement, said, “CPI inflation for the financial year 2025-26 is projected at 4.0 %, with Q1 at 3.6 %; Q2 at 3.9 %; Q3 at 3.8 %; and Q4 at 4.4 %. The risks are evenly balanced,”

The Reserve Bank of India (RBI) has revised its inflation projections, raising the CPI estimate for Q4FY26 to 4.4%, up from 4.2%. The earlier projections for Q1FY26 and Q2FY26 remained unchanged at 4.5% and 4%, respectively.

In its latest policy decision, the RBI’s Monetary Policy Committee (MPC) unanimously voted to reduce the repo rate by 25 basis points, lowering it from 6.25% to 6%.

Following the announcement, the FMCG index surged by as much as 1.41%, touching an intraday high of 55,066.60. Among individual stocks, Emami led the gains with a 2.67% rise, reaching Rs 597.70, while Nestle followed with a 2.36% increase to Rs 2,329.20.

RBI data revealed that headline CPI inflation dropped significantly between December 2024 and February 2025—from 5.2% to 3.6%, a decline of 1.6 percentage points. This sharp fall was mainly due to a seasonal correction in vegetable prices.

Food inflation also fell to a 21-month low of 3.8% in February, while the fuel segment continued to experience deflation. Core inflation, which was stable in December and January, inched up to 4.1% in February due to a surge in gold prices.

The RBI maintains a positive outlook on food inflation, citing seasonal corrections and improved agricultural conditions. Uncertainty around rabi crop output has eased, with second advance estimates pointing to record wheat production and better pulse yields compared to the previous year. Combined with strong Kharif arrivals, these factors are likely to support continued easing in food prices.

Inflation expectations over the next three months and the next year have dropped significantly, helping to anchor the overall inflation outlook. Additionally, the recent dip in crude oil prices is expected to further ease inflationary pressures.

However, the RBI also cautioned about potential risks from global market volatility and possible weather-related disruptions, which could push inflation higher.

Adding to the positive sentiment in FMCG stocks was a forecast from Skymet predicting a normal southwest monsoon for India despite a slow onset. Rate cuts tend to benefit the FMCG sector as they can boost consumer spending and drive demand for everyday goods.

Ready to invest like a pro? Unicorn Signals app equips you with 100+ Free tools and knowledge you need to succeed. Download the Unicorn Signals app and gain access to daily stock lists and insightful market analysis and much more!

MARKETS

Garden Reach Bags Order from Geological Survey of India; Shares Trade Lower 

Ali Waghbakriwala

Shares of Garden Reach Shipbuilders and Engineers Ltd were trading in the red and 3% lower on 9 April despite the company announcing securing an order worth Rs 489.98 crore from the Geological Survey of India.

As per the company’s regulatory filing, the scope of the order covers the design, building, and delivery of two coastal research vessels that have to be delivered within 26 months of the signing of the contract. 

In other news, Garden Reach Shipbuilders and SWAN Defence and Heavy Industries Ltd signed a memorandum of understanding on Tuesday, 8 April to strengthen indigenous commercial shipbuilding capabilities.

The collaboration will concentrate on the construction of commercial boats and offshore structures, with an eye on both international clientele and national marine interests.

Last month, the company signed another Memorandum of Understanding with PWD Nagaland to deliver eight sets of Double Lane Modular Steel bridges to the state. This is Garden Reach’s first MoU with a North-Eastern state. The corporation has not revealed the transaction’s value.

At 12:20 pm, the shares of Garden Reach were trading 1.81% lower at Rs 1,537.40 on NSE. 

Garden Reach Shipbuilders and Engineers Ltd Insights? Let the Analyst Guide You.

Unlock profitable opportunities every day! Unicorn Signals provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Unicorn Signals and start winning now!

MARKETS

Concord Biotech Shares Surge 5% on Receiving USFDA Final Approval 

Ali Waghbakriwala

Shares of the pharmaceutical company Concord Biotech Ltd were trading 5% higher on 9 April after the company announced securing final approval from the US Food and Drug Administration (USFDA) to market its Teriflunomide Tablets, 7 mg and 14 mg.

The medication teriflunomide is used to treat patients with relapsing forms of multiple sclerosis. 

According to IQVIATM, teriflunomide tablet sales are expected to reach over $402 million in the US and $908 million globally, indicating substantial potential for growth both at home and abroad. 

In its regulatory filing, the company said, “The approval reinforces our capability in successfully developing and commercialising a differentiated product portfolio for the US market.”

Concord Biotech, established in 2000, is a research-driven biopharmaceutical firm that specialises in the manufacturing of Active Pharmaceutical Ingredients (APIs) via fermentation and semi-synthetic techniques, as well as final formulations. 

You Might Be Interested In

Concord began as a single-product organisation and has now grown into a full solutions provider, delivering a diverse range of goods across multiple therapeutic categories. The company has created a global presence, with products distributed in over 70 countries, including key markets such as the United States, Europe, Japan, and Latin America, as well as a significant presence in India. 

By establishing strategic partnerships with leading global pharmaceutical companies, Concord is able to expand its product line and reach in both APIs and final formulations.

Concord operates cutting-edge manufacturing facilities in India, including three important sites in Ahmedabad and Gujarat. The Dholka facility, which opened in 2000, concentrates on API production and has received various regulatory certifications, including those from the USFDA, EUGMP, and PMDA. 

Launched in 2016, the Valthera factory produces a variety of oral solids and liquids with the intention to expand into injectable formulations. The Limbasi factory, the most recent extension, was built in 2021 and is dedicated to API manufacturing. It has advanced fermenting and downstream processing capabilities. 

At 11:27 am, the shares of Concord Biotech were trading 1.64% higher at Rs 1,622.80 on NSE.

Curious About Concord Biotech Ltd? Ask the Analyst.

Discover the next big investment! Unicorn Signals’ IPO screener helps you identify promising initial public offerings. Download Unicorn Signals and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!

@2025 - www.equitypandit.com. All Right Reserved.
Latest
IPO
Weekly
Outlook

Stock
Market
Prediction